Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Orbimed Follows Baker Bros and Buys Some Mirati Therapeutics Shares

Orbimed Advisors, a fund focused on the healthcare sector, led by Samuel Isaly, disclosed minutes ago purchasing 125,000 shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX). The fund purchased the shares in one transaction, at a price of $17.50 apiece, increasing its position to a total of 1.3 million shares.

Mirati Therapeutics, Inc

Through the acquisition, Orbimed follows Baker Bros., which recently disclosed buying 400,000 shares of Mirati.

Disclosure: none

Recommended Reading:

Mario Gabelli Takes +5% Stakes in Global Sources Ltd and Belo Corp

Howard Marks Discloses 6.8% of Contango Oil & Gas, Affiliates Close Out of Crimson Exploration

4 Hedge Funds Heavily Invested in Apple’s Fate